Lipidated peptides as anti-obesity agents

0499641 - ÚOCHB 2019 RIV eng P - Patent Document
Maletínská, Lenka - Železná, Blanka - Blechová, Miroslava - Popelová, Andrea
Lipidated peptides as anti-obesity agents.
2018. Owner: Ústav organické chemie a biochemie AV ČR, v. v. i. Date of the patent acceptance: 10.04.2018. Patent Number: US9937235
R&D Projects: GA TA ČR(CZ) TE01020028
Institutional support: RVO:61388963
Keywords : prolactin-releasing peptide * lipidated * obesity
OECD category: Pharmacology and pharmacy
https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20180410&DB=&locale=en_EP&CC=US&NR=9937235B2&KC=B2&ND=4#

Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.
Permanent Link: http://hdl.handle.net/11104/0292008